Back to Sites

Gaborone CRS

Site Number

12701

Address

Gaborone Prevention/Treatment Trials CRS
Princess Marina Hospital
Plot 1836, North Ring Road
Gaborone,
Botswana

IMPAACT Members at this Site

Unoda Chakalisa CRS Coordinator

Tebogo Kakhu CRS Coordinator

Anthony Chibuzor Ogwu CRS Leader

Ayotunde Omoz-Oarhe CRS Leader

Tendani Gaolathe CRS Staff

Loeto Mazhani CRS Staff

Mompati Oganne Mmalane CRS Staff

Sylvester Musa-Aisien CRS Staff

Gaerolwe Masheto CTU Coordinator

Shahin Lockman CTU Principal Investigator

Joseph Moeketsi Makhema CTU Principal Investigator

Sue A. Welsch DAIDS PO

Sikhulile Moyo Laboratory Director

Terence Mohammed Laboratory Manager/Supervisor

Lesedi Tirelo Laboratory QA/QC Coordinator

Motswedi Anderson Laboratory Technician/Technologist

Rufaro L. Mangwarara Pharmacist

Yvonne Mugodi Pharmacist

Tshepho Theodorah Frank Pharmacy Supervisor

Urunduruka Mavis Munamava QA/QC Coordinator

Tumalano Sekoto Regulatory Coordinator

Taolo Agnes Modise Research Nurse

Mpho Raesi Research Nurse

Aida Tesfamaraim Asmelash Staff

Gaerolwe Masheto Staff

Tebogo Mokotedi Staff

Akeem Salawu Staff

Dichaba Siane Staff

Ponego Ponatshego Study Coordinator

Mpho Raesi Study Coordinator

Studies at this Site

1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival)

DAIDS Number

10779

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

P1026S: PK in Pregnancy

DAIDS Number

10040

Research Area

Treatment

Study Status

Closed to Follow Up

P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity

DAIDS Number

10495

Research Area

Treatment

Study Status

Concluded

P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers

DAIDS Number

10638

Research Area

Complications & Comorbidities

Study Status

Concluded

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Treatment

Study Status

Closed to Accrual

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

20721

Research Area

Tuberculosis

Study Status

Enrolling

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

20735

Research Area

Cure

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Complications & Comorbidities

Study Status

Open to Accrual